Neuro-Oncology

Papers
(The H4-Index of Neuro-Oncology is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)
ArticleCitations
HGG-02. NEUROPHYSIOLOGICAL SMALL MOLECULE SCREEN TO TARGET NEURON-GLIOMA INTERACTIONS IN PEDIATRIC HIGH-GRADE GLIOMAS6275
EXTH-68. DUAL METABOLIC REPROGRAMMING BY ONC201/TIC10 AND 2-DEOXYGLUCOSE HAS A STRONG ANTIPROLIFERATIVE EFFECT ON MEDULLOBLASTOMA CELLS1013
NCOG-22. RETROSPECTIVE ANALYSIS OF VISUAL OUTCOMES AFTER BEVACIZUMAB-BASED THERAPY IN OPTIC PATHWAY GLIOMA704
CTNI-49. PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN ß, IN PATIENTS WITH ADVANCED SOLID TUMORS, WITH A PHASE 2 EXPANSION IN RECURRENT GLIOBLASTOMA MUL342
Cognitive outcomes in patients with low-grade glioma244
Reply to the letter regarding “Palliative care and end-of-life care in adults with malignant brain tumors”236
P14.90 Survival outcomes and prognostic factors in glioblastoma patients treated with radiotherapy plus concomitant and adjuvant temozolomide - real-world study224
P14.87 Significance of clinical and molecular-genetic factors for prognosis in 574 adult patients with primary glioblastoma182
EPCT-08. TRIAL WORKING GROUPS FOR PAEDIATRIC BRAIN TUMOURS148
Bone marrow biopsy in PCNSL: Relevant or redundant?131
INNV-18. EFFECT OF DURATION OF TUMOR TREATING FIELDS THERAPY ON CELLULARITY DISTRIBUTIONS BEYOND T1W MRI CONTRAST ENHANCING MARGIN AT AUTOPSY IN GLIOMA PATIENTS: PRELIMINARY RESULTS127
STEM-16. TRYPTOPHANYL tRNA SYNTHETASE (trpRS) FUNCTIONS AS A PRO-STEMNESS CYTOKINE DURING CHEMOTHERAPY IN GLIOBLASTOMA121
INNV-19. NAVIGATING GLIOBLASTOMAS THE DIGITAL WAY: AN OBSERVATIONAL OVERVIEW OF THE USE OF A SMARTPHONE WEB APPLICATION IN A GBM PATIENT POPULATION117
HGG-24. PRECLINICAL EFFICACY OF THE BRAIN PENETRANT CYCLIN-DEPENDENT KINASE INHIBITOR ZOTIRACICLIB IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS104
QOLP-18. QUALITY OF LIFE IN GLIOMAS WHO UNDERWENT AWAKE SURGERY DEPENDS ON RETURN TO SOCIAL LIFE, ABILITY OF MOVEMENT AND VERBAL FLUENCY103
QOLP-25. PERFORMANCE STATUS OF PEDIATRIC PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMORS TREATED IN A TERTIARY CENTER IN MEXICO, A SINGLE-CENTER EXPERIENCE99
LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS97
NIMG-09. DETECTION OF ASYMPTOMATIC MALIGNANT LESIONS BY [18F]FDG PET/MRI IN CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 185
NIMG-67. A SYSTEMATIC REVIEW ON THE DEVELOPMENT OF MACHINE LEARNING MODELS FOR DIFFERENTIATING PCNSL FROM GLIOMAS84
TAMI-76. INTEGRATED MULTI-OMICS REVEAL INTRATUMOUR HETEROGENEITY AND NOVEL THERAPEUTIC TARGETS IN PAEDIATRIC EPENDYMOMA81
Erratum to: Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review80
CTIM-28. MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, FOR RECURRENT GBM DELIVERED BY CONVECTION ENHANCED DELIVERY (CED)74
DIPG-34. IMMUNE SYNAPSE OPTIMIZED GRP78-SPECIFIC CAR T CELLS ELICIT AN IMPROVED ANTITUMOR RESPONSE AGAINST DIPGS73
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas70
Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS70
The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases69
OMIC-14. OPENPBTA: AN OPEN PEDIATRIC BRAIN TUMOR ATLAS69
PATH-16. EVALUATION OF SEX-BASED DIFFERENCES IN CLINICAL OUTCOMES AND TUMOR GENOMICS IN PATIENTS WITH NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA RECEIVING CHEMORADIATION67
EXTH-81. STING ACTIVATION PROMOTES ROBUST IMMUNE RESPONSE AND TUMOR REGRESSION IN GLIOBLASTOMA MODELS65
PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period63
INNV-29. BILATERAL PARIETAL LYMPHOMA LESIONS RESPONDED DIFFERENTLY TO HD-MTX AND RITUXIMAB/TEMOZOLOMIDE THERAPY63
PATH-43. RAMAN SPECTROSCOPY AS A TOOL IN NEUROSURGERY62
BIOM-13. DEVELOPMENT AND VALIDATION OF AN LC-MS/MS ASSAY TO MEASURE GLUTATHIONE, GLUTATHIONE DISULFIDE, CYSTEINE, AND CYSTINE IN HUMAN BRAIN AND HUMAN GLIOBLASTOMA58
P13.09 Inconsistent effect of temozolomide exposure on cell viability in glioblastoma cell line models - a systematic review57
BIOL-06. MIR-1253 POTENTIATES CISPLATIN RESPONSE IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA BY REGULATING FERROPTOSIS57
TMOD-02. GENERATION OF A NOVEL MOUSE MODEL FOR BRAIN TUMORS OF THE DNA METHYLATION CLASS “GBM MYCN”57
Are patients with brain tumours being given timely DVLA advice?56
The role of minimally invasive surgery within a multidisciplinary approach for patients with metastatic spine disease over a decade: A systematic review55
NIMG-22. PREDICTION OF GLIOBLASTOMA CELLULAR INFILTRATION AND RECURRENCE USING MACHINE LEARNING AND MULTI-PARAMETRIC MRI ANALYSIS: RESULTS FROM THE MULTI-INSTITUTIONAL RESPOND CONSORTIUM55
P16.03 Cerebral gliom alters the peripheral CD4+ T helper cell phenotype55
MEDB-89. Elucidation of the Oncogenic role of Nuclear Factor I/B (NFIB) in group 3 medulloblastoma52
DIPG-24. Neurological symptom improvement after re-irradiation in patients with diffuse intrinsic pontine glioma (DIPG): A retrospective analysis of the SIOP-E-HGG/DIPG project.52
ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC51
MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation50
EPEN-20. PDL1 expression and tumor-infiltrating immune cell subpopulations: The role of immune-checkpoint molecules in the prognosis of patients with supratentorial ependymoma and its correlation to s49
ETMR-04. Embryonal tumor with multi-layered rosettes (ETMR) located in the brainstem: a case report on clinical decision-making and a multimodal, interdisciplinary treatment approach including interst49
MEDB-56. POx NPs mediated delivery of (TLR7/8) agonist resiquimod improves treatment outcomes in SHH medulloblastoma by targeting tumor associated macrophages48
DIPG-34. Life and End-of-Life after Diffuse Intrinsic Pontine Glioma diagnosis48
0.040164947509766